In a first effort, an Immunoscore constructed based on the expression of CD8, CD3, CD20 and FOXP3, was applied on a small cohort of stage III melanoma patients showing significant differences in the peri/intratumoral ratio for both CD3 and CD8, with the ratio being higher in patients without recurrence compared to patients with melanoma recurrence, with similar trends for both FOXP3 and CD20 were observed (71). This evidence concerns the gene CD8A and melanoma.